Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 8:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,806 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Allergic Reactions Clear all
Completed Phase 3 Interventional Results available

Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

NCT03627767
View directory record Official record
Conditions
Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases, Skin Diseases, Genetic, Genetic Diseases, Inborn, Skin Diseases, Eczematous, Hypersensitivity, Hypersensitivity, Immediate, Immune System Diseases
Interventions
PF-04965842 100 mg, PF-04965842 200 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
1,235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
52
States / cities
Birmingham, Alabama • Fountain Valley, California • Fremont, California + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily

NCT01147744
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate 100mcg via ACCUHALER/DISKUS, GSK2190915 100mg, GSK2190915 10mg, GSK2190915 300mg, GSK2190915 30mg, Montelukast 10mg, Placebo GSK2190915 one tablet, Placebo montelukast, Placebo fluticasone propionate via ACCUHALER/DISKUS, Placebo GSK2190915 two tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older · Female only
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
22
States / cities
Birmingham, Alabama • Huntington Beach, California • Newport Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Oct 26, 2026, 8:27 AM EDT
Terminated Not applicable Interventional Results available

Spectacle Tints and Thin-Films for Migraine

NCT02720211
View directory record Official record
Conditions
Headache Migraine Chronic
Interventions
Gray tinted spectacle lenses, Thin-Film spectacle lenses
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Phoenix, Arizona • Boston, Massachusetts • Great Neck, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 26, 2026, 8:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Somatosensory Profiles in Individuals With Persistent Musculoskeletal Pain and Inflammatory Bowel Disease

NCT03799471
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Chronic Pain, Central Sensitization
Interventions
Not listed
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 26, 2026, 8:27 AM EDT
Active, not recruiting Phase 2 Interventional

Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents

NCT05347771
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 17 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Phase 2 Interventional Results available

A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma

NCT00994175
View directory record Official record
Conditions
Severe, Refractory Asthma, Airway Inflammation, Airflow Obstruction
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Bethesda, Maryland • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 26, 2026, 8:27 AM EDT
Recruiting Phase 2 Interventional

A Randomized Multicenter Study for Isolated Skin Vasculitis

NCT02939573
View directory record Official record
Conditions
Primary Cutaneous Vasculitis, Cutaneous Polyarteritis Nodosa, IgA Vasculitis, Henoch-Schönlein Purpura
Interventions
Colchicine, Dapsone, Azathioprine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
12
States / cities
Kansas City, Kansas • Boston, Massachusetts • Rochester, Minnesota + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 26, 2026, 8:27 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)

NCT07355075
View directory record Official record
Conditions
Eczema Atopic Dermatitis, Eczema, Atopic Dermatitis
Interventions
GX-03, Vehicle
Combination Product · Other
Lead sponsor
Turn Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Irving, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Telemedicine Education for Rural Children With Asthma

NCT00964301
View directory record Official record
Conditions
Asthma
Interventions
Telemedicine Education, Usual care
Other
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
7 Years to 17 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Not applicable Interventional Results available

Clinical Utility of a PCR Compared to Culture and Sensitivity Testing for the Management of cUTI in Adults.

NCT06996301
View directory record Official record
Conditions
Urinary Tract Infection Complicated, Urinary Tract Infection (cUTI), Urinary Tract Infection (Diagnosis)
Interventions
Treatment guided by the PCR results, Treatment guided by the C&S results
Diagnostic Test
Lead sponsor
Doc Lab Inc
Industry
Eligibility
18 Years and older
Enrollment
773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
San Jose, California • Albany, Georgia • Evans, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients With Asthma

NCT01844401
View directory record Official record
Conditions
Asthma
Interventions
Albuterol Spiromax®, ProAir® HFA
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Costa Mesa, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Oct 26, 2026, 8:27 AM EDT
Not listed Not applicable Interventional

Asthma Learning Project

NCT00874900
View directory record Official record
Conditions
Asthma
Interventions
Educational game, Educational game + motivational interview, Motivational interview
Other
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
7 Years to 15 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 8, 2011 · Synced Oct 26, 2026, 8:27 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer

NCT00910000
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Vorinostat, Carboplatin, Gemcitabine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Phase 2 Interventional

Study of Oglemilast for the Treatment of Asthma

NCT00322686
View directory record Official record
Conditions
Asthma
Interventions
Oglemilast, Placebo then Oglemilast
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2012 · Synced Oct 26, 2026, 8:27 AM EDT
Recruiting Not applicable Interventional

Association Between Body Composition and Pain in Spinal Cord Injury

NCT05459207
View directory record Official record
Conditions
Pain, Inflammatory Response
Interventions
Moderate Fat Meal, High Fat Meal
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Not applicable Interventional Results available

Can a Nasal Decongestant Test Predict Treatment Outcomes in Seasonal Allergic Rhinitis?

NCT00618332
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
mometasone furoate nasal spray, placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 26, 2026, 8:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Contributing Factors in the Pathobiology of Airway Remodeling in Obesity

NCT03115632
View directory record Official record
Conditions
Asthma, Obesity, Obesity, Morbid, Bariatric Surgery Candidate
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Phase 2 Interventional Results available

Multi Immunotherapy to Test Tolerance and Xolair

NCT02626611
View directory record Official record
Conditions
Food Allergy
Interventions
Omalizumab, Food Flour Buildup
Drug
Lead sponsor
Kari Christine Nadeau
Other
Eligibility
4 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Los Angeles, California • Mountain View, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A118G SNP and OPRM1 Gene Opioid-Mediated Effects in Humans

NCT02360371
View directory record Official record
Conditions
Opioid Sensitivity, Individual Difference, Abuse Opioids
Interventions
Within-subject test of blinded study medication
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Not applicable Interventional

Schema, Emotion, and Behavior Therapy for Children

NCT01784263
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Individual Cognitive Behavioral Therapy, Standard Community Treatment
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
9 Years to 13 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma

NCT00679263
View directory record Official record
Conditions
Asthma
Interventions
MN-221, Placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
4
States / cities
Lenexa, Kansas • North Dartmouth, Massachusetts • Rolla, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2011 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Phase 4 Interventional Results available

The Study of Soy Isoflavones in Asthma

NCT01052116
View directory record Official record
Conditions
Asthma
Interventions
Soy isoflavone supplement, Placebo
Drug
Lead sponsor
American Lung Association Asthma Clinical Research Centers
Other
Eligibility
12 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
18
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 26, 2026, 8:27 AM EDT
Terminated Not applicable Interventional

Kansas City Community Environmental Remediation And Training (KC CERT)

NCT00144443
View directory record Official record
Conditions
Asthma, Rhinitis, Allergy
Interventions
Basic home repair, Asthma Trigger Education
Behavioral
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
2 Years to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Phase 2 Interventional

A Study of JNJ-38518168 in Symptomatic Adult Participants With Uncontrolled, Persistent Asthma

NCT01823016
View directory record Official record
Conditions
Asthma
Interventions
Placebo, JNJ-38518168
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
20
States / cities
Scottsdale, Arizona • Los Angeles, California • Mission Viejo, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 26, 2026, 8:27 AM EDT